Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +62

Intuitive Surgical stock balances 22% growth against legal charge

Antitrust case Earnings report Legal settlement AI-generated analysis

πŸ“ˆ Intuitive Surgical revenue jumped 22% year-over-year to $3.05 billion, driven by a 15% increase in worldwide procedures across da Vinci and Ion platforms.

πŸ”§ System placements accelerated significantly with 546 da Vinci systems installed in the quarter versus 427 last year, including 315 new da Vinci 5 units.

βš–οΈ A proposed antitrust settlement resulted in a $450 million pretax charge that reduced GAAP net income to $523 million or $1.49 per diluted share.

πŸ’° On a non-GAAP basis excluding the legal charge, net income rose to $1.05 billion and adjusted diluted earnings reached $3.00 per share.

🎯 Management forecasts worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range for the remainder of 2026.

πŸ’Ή The company projects a non-GAAP gross margin between 68.7% and 69.3% with operating expenses growing 11% to 13% under current tariff assumptions.

πŸ“‰ GAAP earnings per share declined from $1.95 in the prior-year quarter due to the one-time legal charge impacting reported profitability.

πŸš€ Ion platform procedures advanced by 31%, demonstrating strong adoption of the company's newer robotic technology alongside established da Vinci systems.

πŸ’Ά Intuitive Surgical stock price rose 1.10% to 393.63 euros following the release of the quarterly earnings report and guidance update.

πŸ›‘οΈ The antitrust agreement includes injunctive relief without an admission of liability, subject to preliminary and final court approval.

Bullish Signals
  • Intuitive Surgical achieved a 22% year-over-year revenue increase to $3.05 billion, demonstrating strong top-line growth driven by procedure volume.
  • Worldwide procedures grew approximately 15%, with da Vinci procedures rising 14% and Ion procedures surging 31%, indicating broad platform adoption.
  • The company placed 546 da Vinci systems in the quarter, a significant increase from 427 last year, including 315 new da Vinci 5 units.
  • Non-GAAP net income increased to $1.05 billion and adjusted diluted earnings rose to $3.00 per share, excluding the one-time legal charge.
  • Management expects worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range for the rest of 2026.
  • Instruments and accessories revenue grew 18% to $1.80 billion, showing strong recurring revenue potential from consumables.
Risk Factors
  • A proposed antitrust settlement triggered a $450 million pretax charge that significantly reduced GAAP net income to $523 million.
  • GAAP earnings per share fell to $1.49 from $1.95 in the prior-year quarter due to the impact of the legal settlement charge.
  • The antitrust agreement remains subject to preliminary and final court approval, introducing regulatory uncertainty regarding the timing of the charge recognition.
Full Analysis
Intuitive Surgical reported robust third-quarter financial performance for the period ended September 30, 2026, driven by significant growth in its core robotic surgery business. Total revenue surged 22% year-over-year to reach $3.05 billion, fueled by a 15% increase in worldwide procedures across both da Vinci and Ion platforms. System placements also accelerated, with the company installing 546 da Vinci systems compared to 427 in the prior-year quarter. Despite strong operational metrics, reported earnings were impacted by a substantial proposed antitrust settlement related to class-action litigation. This event triggered a $450 million pretax charge that reduced GAAP net income to $523 million, or $1.49 per diluted share, down from $704 million in the previous year. However, on a non-GAAP basis which excludes this one-time charge, net income rose to $1.05 billion and adjusted diluted earnings increased to $3.00 per share. Management maintains optimistic guidance for the remainder of 2026, projecting worldwide da Vinci procedure growth near the midpoint of its 14% to 15% target range. The company also forecasts a non-GAAP gross margin between 68.7% and 69.3%, with operating expenses expected to grow 11% to 13%. These figures assume current tariff conditions remain stable through year-end, highlighting the company's continued focus on profitability despite legal headwinds. Intuitive Surgical stock traded at 393.63 euros on November 3, 2026, reflecting a 1.10% gain following the report release. The divergence between strong underlying procedure volume growth and the drag from the legal settlement illustrates the company's ability to expand its market footprint while navigating significant regulatory challenges.